Replies to post #129296 on Biotech Values

[mcbio]

Ok thanks mcbio. I can't remember which analyst report it was, but that was the order they cited. But the launch dates vary btn research shops.

Thanks for that update.

It's also important to note, too, that the first of the fostamatinib trials expected to report in 2H12 is also likely the most difficult (#msg-64248852 ). If AZN reports negative results from this initial trial and RIGL gets crushed, as I suspect it might, I'd view that as potentially an ideal buying opportunity as I agree with jq that the subsequent trials are more likely to be positive and RIGL actually has a bit of a pipeline beyond fostamatinib as well.